Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander M Spence

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Cancer Research|April 16, 2009
Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomasMindy D Szeto, Gargi Chakraborty, Jennifer Hadley, et al.
Surgical Neurology International|September 18, 2010
Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survivalRohan Ramakrishna, Jason Barber, Greg Kennedy, et al.
Molecular Imaging|August 19, 2003
Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient resultsJoanne M Wells, David A Mankoff, Janet F Eary, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 19, 2008
Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomasKristin R Swanson, Gargi Chakraborty, Christina H Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imagingJoseph G Rajendran, David A Mankoff, Finbarr O'Sullivan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matterAlexander M Spence, Mark Muzi, David A Mankoff, et al.
Investigational New Drugs|October 31, 2003
A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium reportSusan M Chang, John G Kuhn, H Ian Robins, et al.
International Journal of Radiation Oncology, Biology, Physics|October 26, 2005
[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failureJames G Douglas, Keith J Stelzer, David A Mankoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapyMichael S Bobola, Mary J Emond, A Blank, et al.
Cancer|April 2, 2011
A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomasWilliam T Couldwell, Amy A Surnock, Alfonso J Tobia, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Cancer Research|April 16, 2009
Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomasMindy D Szeto, Gargi Chakraborty, Jennifer Hadley, et al.
Surgical Neurology International|September 18, 2010
Imaging features of invasion and preoperative and postoperative tumor burden in previously untreated glioblastoma: Correlation with survivalRohan Ramakrishna, Jason Barber, Greg Kennedy, et al.
Molecular Imaging|August 19, 2003
Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient resultsJoanne M Wells, David A Mankoff, Janet F Eary, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 19, 2008
Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomasKristin R Swanson, Gargi Chakraborty, Christina H Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imagingJoseph G Rajendran, David A Mankoff, Finbarr O'Sullivan, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2004
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matterAlexander M Spence, Mark Muzi, David A Mankoff, et al.
Investigational New Drugs|October 31, 2003
A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium reportSusan M Chang, John G Kuhn, H Ian Robins, et al.
International Journal of Radiation Oncology, Biology, Physics|October 26, 2005
[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failureJames G Douglas, Keith J Stelzer, David A Mankoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapyMichael S Bobola, Mary J Emond, A Blank, et al.
Cancer|April 2, 2011
A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomasWilliam T Couldwell, Amy A Surnock, Alfonso J Tobia, et al.
Pageof 4